1998
Intraoperative brachytherapy, laryngopharyngoesophagectomy, and gastric transposition for patients with recurrent hypopharyngeal and cervical esophageal carcinoma
Wilson L, Chung J, Haffty B, Cahow E, Sasaki C, Son Y. Intraoperative brachytherapy, laryngopharyngoesophagectomy, and gastric transposition for patients with recurrent hypopharyngeal and cervical esophageal carcinoma. The Laryngoscope 1998, 108: 1504-1508. PMID: 9778290, DOI: 10.1097/00005537-199810000-00014.Peer-Reviewed Original ResearchConceptsExternal beam radiationGastric transpositionCervical esophagusLocal controlMedian doseRecurrent carcinomaActuarial local controlCervical esophageal carcinomaLymphvascular space invasionTotal median doseLymph node dissectionGood local controlAcceptable risk profileActuarial survivalNode dissectionFacial painNodal involvementOverall survivalRecurrent diseaseCervical abscessIntraoperative brachytherapyMale patientsMedian ageMucosal hemorrhageFacial edema
1997
Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
Haffty B, Son Y, Wilson L, Papac R, Fischer D, Rockwell S, Sartorelli A, Ross D, Sasaki C, Fischer J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. International Journal Of Cancer 1997, 5: 235-245. PMID: 9372546, DOI: 10.1002/(sici)1520-6823(1997)5:5<235::aid-roi4>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaWhite blood cell countPhase I trialCell carcinomaRadiation therapyMitomycin CNonhematological toxicitiesI trialStage III/IV squamous cell carcinomaCourse of RTTotal median doseAcceptable toxicity profilePhase III trialsCurrent ongoing trialsDisease survival ratesDaily radiation therapyBlood cell countHypoxic cell cytotoxinActuarial survivalHemoglobin nadirsAdvanced diseaseMedian doseIII trialsOngoing trialsMultiinstitutional trial